Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report specifically addresses a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) related to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding internal plan transactions rather than a financial performance report.
Material Changes
Following a revaluation of the cash element of the notional investment held within the GSK 401K plan, there was an increase in the notional allocation of American Depositary Shares (ADSs) on March 14, 2014. The transaction price was $54.23 per ADS.
- Dr M M Slaoui: Increase of 17 ADSs.
- Dr K Slaoui: Increase of 28 ADSs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports on compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- The reported ADS increases resulted from a plan revaluation, not direct market purchases by the individuals.
- The transaction price of $54.23 per ADS reflects the valuation on March 14, 2014.
- The filing confirms compliance with UK Disclosure and Transparency Rules regarding director transactions.